- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.01. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 27.12.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 20.12.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 02.12.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 01.11.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 29.10.24 | Pre-market Movers: GlycoMimetics, BIO-key International, Lixte Biotechnology, Shuttle Pharmaceuticals, Profire Energy | 491 | AFX News | NORWALK (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green GlycoMimetics, Inc. (GLYC) is up over 163% at $0.4433.
BIO-key... ► Artikel lesen | |
| LIXTE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 23.10.24 | Lixte Biotechnology granted extension to meet Nasdaq listing rules | 3 | Investing.com | ||
| 23.10.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.10.24 | Lixte Biotechnology files to sell units, no amount given | 14 | Seeking Alpha | ||
| 23.10.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 05.09.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.09.24 | Lixte Biotechnology Holdings, Inc.: LIXTE Receives U.S. Patent Issue Notification for Immune Oncology | 130 | GlobeNewswire (Europe) | Patent Covers Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW)... ► Artikel lesen | |
| 26.08.24 | Lixte Biotechnology Holdings, Inc.: First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company | 165 | GlobeNewswire (Europe) | PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) ("LIXTE" or the "Company"), today announced the dosing of the first patient in a new... ► Artikel lesen | |
| 23.08.24 | Lixte Biotechnology faces Nasdaq delisting over equity shortfall | 2 | Investing.com | ||
| 19.08.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08.24 | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Provides Update On Recent Activities and Developments | 285 | GlobeNewswire (Europe) | -Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company- -Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer- -Preclinical... ► Artikel lesen | |
| 15.08.24 | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings to Present at Two Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 15.08.24 | Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event | 270 | ACCESS Newswire | NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing... ► Artikel lesen | |
| 08.08.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.06.24 | Lixte, Roche, Netherlands Cancer Institute Collaborate For Colon Cancer Trial; Stock Up | 512 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - Lixte Biotechnology Holdings, Inc. (LIXT), Friday announced a partnership with Swiss healthcare company Roche Holding AG (RHHBY) and the Netherlands Cancer Institute... ► Artikel lesen |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 2,200 | -0,90 % | Inovio Pharmaceuticals Prices $30 Mln Public Offering With Warrants | WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals, Inc. (INO), a clinical-stage biotechnology company, Friday announced the pricing of a public offering of 10 million common shares and also warrants... ► Artikel lesen | |
| OCUGEN | 0,759 | +1,74 % | Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200-a Novel Integrin-Targeting Biologic for Diabetic Macular Edema | MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene... ► Artikel lesen | |
| MAINZ BIOMED | 5,695 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed initiiert klinische US-Studie zur Evaluierung der Leistungsfähigkeit des Tests der nächsten Generation zur Erkennung von fortgeschrittenen Adenomen in einer großen Patientenpopulation | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studie
Mainz Biomed initiiert klinische US-Studie zur Evaluierung der Leistungsfähigkeit des Tests der nächsten Generation... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,470 | -0,24 % | Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week | ||
| IMMUNITYBIO | 2,980 | -0,03 % | IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? | ||
| MARINOMED BIOTECH | 14,600 | +1,39 % | Marinomed Biotech: Neustart nach Ende des Sanierungsverfahrens | Die Marinomed Biotech AG hat das im August 2024 eröffnete Sanierungsverfahren abgeschlossen. Wie das österreichische Biotech-Unternehmen am Montag mitteilte, wurde der Prozess nach Erfüllung aller Bedingungen... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,520 | 0,00 % | Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down - Should You Sell? | ||
| ORAGENICS | 0,282 | 0,00 % | Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO | SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided... ► Artikel lesen | |
| FIBROGEN | 0,472 | -2,98 % | FibroGen Aktie: Vorzeigemodell für Erfolg! | Die FibroGen Aktie verzeichnete am 21. Dezember 2024 einen beachtlichen Anstieg von 5,13 Prozent und schloss bei 0,41 EUR. Der Biotechnologiekonzern, der sich auf die Entwicklung von Therapeutika für... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,005 | 0,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure | TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| CAPRICOR | 13,920 | -0,29 % | Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy | -If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku- ... ► Artikel lesen | |
| BIOLINERX | 0,107 | -2,73 % | BioLineRx Ltd.: BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares | TEL AVIV, Israel, Jan. 17, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing... ► Artikel lesen | |
| RADIUS HEALTH | - | - | Radius Health: Radius Pharmaceuticals Announces Licensing Agreement with Pharmanovia to Register and Commercialize Abaloparatide in China and Select Asia Pacific Territories | BOSTON, MA / ACCESSWIRE / January 2, 2025 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused... ► Artikel lesen | |
| MARKER THERAPEUTICS | 2,140 | 0,00 % | MRKR stock touches 52-week low at $2.4 amid challenging year | ||
| COCRYSTAL | 1,890 | +1,61 % | Cocrystal Pharma, Inc.: Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 | Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuationsEnrollment to be extended due to low influenza infection among challenged... ► Artikel lesen |
Das Unternehmen LIXTE BIOTECHNOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIXTE BIOTECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.
